Baricitinib, Methotrexate as Monotherapy or Combination in the Treatment of Rheumatoid Arthritis - an Open Label Randomized Clinical Trial

Last updated: April 12, 2023
Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Overall Status: Active - Recruiting

Phase

4

Condition

Rheumatoid Arthritis

Dermatomyositis (Connective Tissue Disease)

Musculoskeletal Diseases

Treatment

N/A

Clinical Study ID

NCT05827497
BSMMU/2022/10476
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The goal of this open-label randomized clinical trial is to assess the efficacy of baricitinib 2 mg in comparison to methotrexate 25 mg as monotherapy followed by baricitinib 4 mg in comparison to methotrexate 10 mg and baricitinib 2 mg combination in patients with rheumatoid arthritis with moderate to severe disease activity. The main question it aims to answer:

• Is there any difference in the efficacy of baricitinib as monotherapy in comparison to methotrexate monotherapy or methotrexate-baricitinib combination in the treatment of rheumatoid arthritis

Eligibility Criteria

Inclusion

Inclusion Criteria:

    1. Patients more than 18 years of age 2. Patients fulfill the ACR/EULAR 2010classification criteria for Rheumatoid arthritis 3. Patients with DAS 28 ESR> 3.2

Exclusion

Exclusion Criteria:

    1. Recent or concurrent infection including active tuberculosis 2. Haemoglobin (Hb) < 9 gm/dl 3. Total WBC count < 4000 / µL 4. Neutrophil count < 1200 / µL 5. Lymphocytecount < 750 / µL 6. AST/ALT > three times the upper limit of normal 7. Estimatedglomerular filtration rate < 60 ml/minute/1.73 m2 8. Co-morbid illness- e.g.,Malignancy 9 . Pregnant or breast feeding woman

Study Design

Total Participants: 132
Study Start date:
April 01, 2023
Estimated Completion Date:
March 31, 2024

Study Description

This open-label randomized clinical trial will be conducted in the department of rheumatology, BSMMU. The rheumatoid arthritis patients with moderate to high disease activity at baseline, disease activity score (DAS28ESR>3.2) will be considered as primary entry criteria for this study. Consecutive sampling method will be applied. The study will be done in 2 phases, duration of each phase 24 weeks. Considering inclusion and exclusion criteria, total 132 patients are randomized into group A and group B following block randomization. Each group will be consisting of 66 patients. In phase 1 Group A will be put on baricitinib 2 mg once daily and Group B will be put on methotrexate 25 mg weekly. The patients who fail to achieve remission or low disease activity by 24 weeks eligible for entry into phase 2 where group A will be put on baricitinib 4 mg and group B will be put on baricitinib 2 mg in combination with methotrexate 10 mg. Follow-up will be done at the 4th, 12th and 24th week in phase 1 and 28th, 36th and 48th week in phase 2. Response to treatment will be evaluated by DAS 28 ESR. At the end of 24th week endpoint for efficacy will be assessed at by DAS 28ESR. Adverse effects will be assessed by history, physical examinations and investigations.

Results will be compared among two groups with a 95% confidence interval and a p-value of < 0.05. The degrees of statistical significance between groups will be analyzed by unpaired t-test and/or Mann-Whitney U test. Qualitative data in between groups will be analyzed by the chi-square test. Probabilities of associations will be assessed by calculating Spearman´s rank correlation coefficient

Connect with a study center

  • Dr. Md. Abu Shahin

    Dhaka,
    Bangladesh

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.